ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
2 hedge funds and large institutions have $18K invested in ELITE PHARMACEUTICAL in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
36% less capital invested
Capital invested by funds: $28K → $18K (-$10K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFAG
Blackston Financial Advisory Group
The Villages,
Florida
|
-$8.54K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$7K |
ELI Hedge Fund Activity: Q1 2022 in Review
2 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2022, worth a combined $18K — down 36% from $28K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ELI and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was Blackston Financial Advisory Group, cutting an estimated $8.54K.
- 2 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q1 2022, down from 3 in Q4 2021.
- Funds reported $18K of ELITE PHARMACEUTICAL stock for Q1 2022, down 36% quarter-over-quarter.
- 0 funds opened new ELITE PHARMACEUTICAL positions in Q1 2022 and 1 closed out, a net change of -1 holder.
- The largest ELITE PHARMACEUTICAL seller in Q1 2022 was Blackston Financial Advisory Group, an estimated $8.54K sold.
Based on aggregated 13F filings for Q1 2022.